Immune Checkpoint Inhibitors in Gliomas

Current Oncology Reports

Volumn 19, Issue 4, 2017, Pages

  Tan, Aaron C ^a   Heimberger, Amy B ^b   Khasraw, Mustafa ^c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anti CTLA 4; Anti PD 1; Anti PD L1; Glioblastoma; Glioma; Immune checkpoint inhibitors

Indexed keywords

AMP 224; AMP 514; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BIOLOGICAL MARKER; BMS 936559; BMS 986016; DURVALUMAB; IMP 321; IPILIMUMAB; LIRILUMAB; MEDI 6383; MSB 001135930; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; REGN 2810; TICILIMUMAB; TRX 518; UNCLASSIFIED DRUG; URELUMAB; VARLILUMAB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GERMLINE MUTATION; GLIOMA; HUMAN; OUTCOME ASSESSMENT; REVIEW; SOMATIC MUTATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANIMALS; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 85015719783     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-017-0586-5     Document Type: Review

References (88)

1. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep. 2010;12(1):26–33. doi:10.1007/s11912-009-0077-4.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66. doi:10.1016/s1470-2045(09)70025-7.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
4. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(17):1974–82. doi:10.1200/jco.2014.59.4358.
5. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84. doi:10.1016/s1470-2045(15)70076-8.
6. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(13):1430–7. doi:10.1200/jco.2014.59.0703.
7. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15(1):69–77. doi:10.1016/s1470-2045(13)70551-5.
8. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44. doi:10.1056/NEJMoa1305133.
9. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. doi:10.1056/NEJMoa1507643.
10. Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65. doi:10.1016/s1470-2045(15)70054-9.
11. Nduom EK, Wei J, Yaghi NK, Huang N, Kong L-Y, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. J Neuro-Oncol. 2016;18(2):195–205. doi:10.1093/neuonc/nov172. This study demonstrates the rates of PD-L1 expression in glioblastoma, which is increasingly used for eligibility criteria in clinical trials.
12. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623–35. doi:10.1038/nri3265.
13. Brooks WH, Markesbery WR, Gupta GD, Roszman TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol. 1978;4(3):219–24. doi:10.1002/ana.410040305.
14. Boker DK, Kalff R, Gullotta F, Weekes-Seifert S, Mohrer U. Mononuclear infiltrates in human intracranial tumors as a prognostic factor. Influence of preoperative steroid treatment. I. Glioblastoma. Clin Neuropathol. 1984;3(4):143–7.
15. Palma L, Di Lorenzo N, Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg. 1978;49(6):854–61. doi:10.3171/jns.1978.49.6.0854.
16. Rossi ML, Jones NR, Candy E, Nicoll JA, Compton JS, Hughes JT, et al. The mononuclear cell infiltrate compared with survival in high-grade astrocytomas. Acta Neuropathol. 1989;78(2):189–93.
17. Safdari H, Hochberg FH, Richardson Jr EP. Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol. 1985;23(3):221–6.
18. Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, et al. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014;110(10):2560–8. doi:10.1038/bjc.2014.162. This paper is important in revealing different populations of TILs which may correlate with prognosis.
19. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14(16):5166–72. doi:10.1158/1078-0432.ccr-08-0320.
20. El Andaloussi A, Lesniak MS. An increase in CD4 + CD25 + FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-Oncology. 2006;8(3):234–43. doi:10.1215/15228517-2006-006.
21. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology. 2016. doi:10.1093/neuonc/now132.
22. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–87. doi:10.1038/nrc.2016.36.
23. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165–75. doi:10.1158/1078-0432.ccr-12-3314.
24. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology. 2015;17(8):1064–75. doi:10.1093/neuonc/nou307.
25. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res. 2016;4(2):124–35. doi:10.1158/2326-6066.cir-15-0151.
26. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20(20):5290–301. doi:10.1158/1078-0432.ccr-14-0514.
27. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007;13(7):2158–67. doi:10.1158/1078-0432.ccr-06-2070.
28. vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med. 2013;210(13):2803–11. doi:10.1084/jem.20130678.
29. Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry Jr WT. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother (Hagerstown, Md: 1997). 2012;35(5):385–9. doi:10.1097/CJI.0b013e3182562d59.
30. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–9. doi:10.1016/j.ijrobp.2012.12.025.
31. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF et al. Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology. 2016 (just-accepted):00-.
32. Reardon DA, Okada H. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neuro-Oncol. 2015;123(3):339–46. doi:10.1007/s11060-015-1748-7.
33. Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neuro-Oncol. 2016. doi:10.1007/s11060-016-2190-1.
34. Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland P. Ipilimumab and bevacizumab in glioblastoma. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016. doi:10.1016/j.clon.2016.04.042.
35. Schaff LR, Lassman AB, Goldlust SA, Cloughesy T, Singer S, Schwartz GK, et al. ET-53 ipilimumab for recurrent glioblastoma (GBM). Neuro-Oncology. 2014;16 suppl 5:v90. doi:10.1093/neuonc/nou255.50.
36. Hu J, Yu J, Black K, Rudnick J. IT-13Ipilimumab for recurrent high-grade glioma: a single-institution case series. Neuro-Oncology. 2014;16 suppl 5:v112. doi:10.1093/neuonc/nou258.11.
37. Brown NF, Carter T, Shaw HM, Cohn-Brown D, Chester K, Mulholland PJ, et al. Sequential immune checkpoint inhibition with concurrent bevacizumab for relapsed glioblastoma: a single centre experience. ASCO Meeting Abs. 2016;34:e13514.
38. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol Off J Am Soc Clin Oncol. 2016. doi:10.1200/jco.2016.66.6552. This report of two pediatric patients with extraordinary high mutational loads responding to nivolumab suggests the hypermutator phenotype may be sensitive to immune checkpoint inhibitors.
39. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65. doi:10.1016/s1470-2045(12)70090-6.
40. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–83. doi:10.1016/s1470-2045(16)30053-5.
41. Sampson JH, Vlahovic G, Desjardins A, Friedman HS, Baehring JM, Hafler D et al. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). ASCO Meeting Abstracts. 2014;32(15_suppl):TPS2101.
42. Sampson JH, Vlahovic G, Sahebjam S, Omuro AMP, Baehring JM, Hafler DA et al. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. ASCO Meeting Abstracts. 2015;33(15_suppl):3010.
43. Reardon DA, Sampson JH, Sahebjam S, Lim M, Baehring JM, Vlahovic G et al. Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. ASCO Meeting Abstracts. 2016;34(15_suppl):2014.
44. Wick W, Brandes AA, Gorlia T, Bendszus M, Sahm F, Taal W et al. EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. ASCO Meeting Abstracts. 2016;34(15_suppl):2001.
45. Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, Li G et al. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. ASCO Meeting Abstracts. 2015;33(15_suppl):2009.
46. Reardon DA, De Groot JF, Colman H, Jordan JT, Daras M, Clarke JL et al. Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). ASCO Meeting Abstracts. 2016;34(15_suppl):2010.
47. Reardon DA, Kaley TJ, Dietrich J, Lim M, Dunn GP, Gan HK et al. Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS2080.
48. Sampson JH, Omuro AMP, Preusser M, Lim M, Butowski NA, Cloughesy TF et al. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS2079.
49. Binder DC, Davis AA, Wainwright DA. Immunotherapy for cancer in the central nervous system: current and future directions. Oncoimmunol. 2016;5(2), e1082027. doi:10.1080/2162402x.2015.1082027.
50. Sahebjam S, Johnstone PA, Forsyth PAJ, Arrington J, Vrionis FD, Etame AB et al. Safety and antitumor activity of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab (Pembro) and bevacizumab (Bev) in patients (pts) with recurrent high grade gliomas: Preliminary results from phase I study. ASCO Meeting Abstracts. 2016;34(15_suppl):2041.
51. Fried I, Weintraub M, Ben Ami T, Shen R, Benifla M, Mordechai A, et al. IT-11A PHASE I/II clinical trial of CT-011 (PIDILIZUMAB) in diffuse intrinsic pontine glioma and relapsed high grade glioma: a preliminary report. Neuro-Oncology. 2014;16 suppl 5:v111–2. doi:10.1093/neuonc/nou258.9.
52. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690.
53. Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47. doi:10.1186/s13045-016-0277-y.
54. Berghoff AS, Pajenda S, Ilhan-Mutlu A, Widhalm G, Dieckmann K, Hainfellner JA et al. Correlation of plasma PD-L1 detectability with age in glioma patients. ASCO Meeting Abstracts. 2015;33(15_suppl):e13039.
55. Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology. 2009;11(4):394–402. doi:10.1215/15228517-2008-104.
56. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204. doi:10.1186/1479-5876-9-204.
57. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009;87(2):365–71. doi:10.1016/j.athoracsur.2008.10.067. discussion 71–2.
58. Schumacher Ton N, Kesmir C, van Buuren Marit M. Biomarkers in cancer immunotherapy. Cancer Cell. 2015;27(1):12–4.
59. Champiat S, Ferté C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunol. 2014;3(1), e27817.
60. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99. doi:10.1056/NEJMoa1406498.
61. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24(5):743–50.
62. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA oncol. 2015;1(9):1319–23.
63. Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, et al. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 2015;75(17):3446–55.
64. Tiffany R. Hodges, Martina Ott, Joanne Xiu, Zoran Gatalica, Jeff Swensen, Shouhao Zhou, Jason T. Huse, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neurooncology 2017 [in press]
65. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75. doi:10.1200/jco.2009.26.7609.
66. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. doi:10.1056/NEJMoa1500596. This trial importantly shows a correlation between benefit to anti-PD1 antibody (pembrolizumab) and mismatch-repair status.
67. Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) genetic/familial high-risk assessment: colorectal, Version 2.2015. 2016.
68. Leung SY, Chan TL, Chung LP, Chan ASY, Fan YW, Hung KN, et al. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol. 1998;153(4):1181–8. doi:10.1016/S0002-9440(10)65662-3.
69. Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230–6. doi:10.1158/2159-8290.cd-16-0575.
70. Lee V, Murphy A, Le DT, Diaz Jr LA. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016. doi:10.1634/theoncologist.2016-0046.
71. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13(7):2038–45. doi:10.1158/1078-0432.ccr-06-2149.
72. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8. doi:10.1038/nature07385.
73. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15(14):4622–9. doi:10.1158/1078-0432.ccr-08-3012.
74. Xie C, Sheng H, Zhang N, Li S, Wei X, Zheng X. Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. Mol Clin Oncol. 2016;5(2):236–40. doi:10.3892/mco.2016.907.
75. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (New York, NY). 2014;343(6167):189–93. doi:10.1126/science.1239947.
76. van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015;129(4):597–607. doi:10.1007/s00401-015-1403-6.
77. Rodriguez-Hernandez I, Garcia JL, Santos-Briz A, Hernandez-Lain A, Gonzalez-Valero JM, Gomez-Moreta JA, et al. Integrated analysis of mismatch repair system in malignant astrocytomas. PLoS One. 2013;8(9), e76401. doi:10.1371/journal.pone.0076401.
78. Manson G, Norwood J, Marabelle A, Kohrt H, Houot R. Biomarkers associated with checkpoint inhibitors. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2016;27(7):1199–206. doi:10.1093/annonc/mdw181.
79. Sims JS, Ung TH, Neira JA, Canoll P, Bruce JN. Biomarkers for glioma immunotherapy: the next generation. J Neuro-Oncol. 2015;123(3):359–72. doi:10.1007/s11060-015-1746-9.
80. Jackson CM, Lim M, Drake CG. Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res. 2014;20(14):3651–9. doi:10.1158/1078-0432.ccr-13-2057.
81. Sanmamed MF, Chester C, Melero I, Kohrt H. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2016;27(7):1190–8. doi:10.1093/annonc/mdw041.
82. Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2016;27(2):214–24. doi:10.1093/annonc/mdv550.
83. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(10):1020–30. doi:10.1200/jco.2013.53.0105.
84. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65. doi:10.1093/jnci/djs629.
85. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–42. doi:10.1016/s1470-2045(15)00088-1.
86. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro-Oncology. 2011;13(1):3–13. doi:10.1093/neuonc/noq169.
87. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2015;26(12):2375–91. doi:10.1093/annonc/mdv383.
88. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2015;26(9):1824–9. doi:10.1093/annonc/mdv182.